Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT05068388

Effect of Oral (Z)-Endoxifen in Premenopausal Women With Measurable Breast Density

A Phase 2, Randomized, Double-blinded, Placebo-controlled, Dose-Response Study of Oral (Z)-Endoxifen in Premenopausal Women With Measurable Breast Density

Status
Active Not Recruiting
Phase
Phase 2
Study type
Interventional
Enrollment
240 (actual)
Sponsor
Atossa Therapeutics, Inc. · Industry
Sex
Female
Age
40 Years – 55 Years
Healthy volunteers
Accepted

Summary

This is a randomized, double-blinded, placebo-controlled dose-response efficacy study of oral (Z)-endoxifen in premenopausal women with measurable breast density. There will be 5 in-clinic visits (Screening, Day 1, Months 1, 3 and 6) and 3 self-report visits (Months 2, 4 and 5). Standard of care mammograms will be used for the screening mammogram as well as the 24-month follow up visit.

Conditions

Interventions

TypeNameDescription
DRUGZ-EndoxifenZ-Endoxifen
DRUGPlaceboPlacebo

Timeline

Start date
2021-12-21
Primary completion
2024-08-28
Completion
2025-12-31
First posted
2021-10-05
Last updated
2024-04-26

Locations

1 site across 1 country: Sweden

Source: ClinicalTrials.gov record NCT05068388. Inclusion in this directory is not an endorsement.